QBSAU - Qu Biologics
Alternative Names: QBSAU SSILatest Information Update: 28 Jun 2025
At a glance
- Originator Qu Biologics
- Class Antineoplastics; Antirheumatics; Bacterial antigens; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Bone cancer; Breast cancer; Rheumatoid arthritis; Skin cancer
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Bone-cancer in Canada (SC)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Breast-cancer in Canada (SC)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Canada (SC)